Rituxan reduces risk of cancer recurrence, study shows

05/20/2010 | Bloomberg Businessweek

Biogen Idec and Genentech's Rituxan reduced the risk of follicular lymphoma recurrence by 50% during a late-stage trial in patients who respond to chemotherapy, according a study. Although the Rituxan group became prone to infection because of the drug, a study author said the treatment "is likely to become a new standard of care for these patients."

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX